Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis appoints Rob Kowalski as Chief People & Organization Officer
01:00am, Monday, 28'th Jun 2021
Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He w
Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients
07:24am, Monday, 21'st Jun 2021
Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for spinal muscular atrophy (SMA). The da
Novartis CEO says future pandemics are bound to happen. Here's how to prepare for the next one
08:15am, Wednesday, 16'th Jun 2021
The CEO of Swiss pharmaceutical giant Novartis on Wednesday outlined how policymakers and the healthcare industry can improve pandemic preparedness.
4 Buy-Rated Giants Pay a Dividend of at Least 3%
01:27pm, Friday, 11'th Jun 2021
Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%.
Novartis to close Swiss plant, 50 jobs to go
08:41am, Wednesday, 09'th Jun 2021
Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.
3 Best Global Dividend Aristocrats You Can Safely Buy Today
09:23pm, Tuesday, 08'th Jun 2021
Dividend aristocrats have proven to be one of the best ways to retire rich over time. But today they are 30% overvalued. Foreign dividend blue chips are 19% overvalued, including global aristocrats. B
Novartis CEO on new cancer therapy programs
06:26pm, Monday, 07'th Jun 2021
CNBC's Meg Tirrell talks to Dr. Vasant Narasimhan, CEO of Novartis, about his company's new cancer therapy, which uses targeted microdoses of radiation to combat cancer. For access to live and exclusi
Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
01:32pm, Monday, 07'th Jun 2021
Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.
Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival
03:10pm, Friday, 04'th Jun 2021
Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuro
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO
02:17pm, Friday, 04'th Jun 2021
Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.
Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
03:21pm, Thursday, 03'rd Jun 2021
Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA
Basel, June 3, 2021 — Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated sig
Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis
07:05am, Wednesday, 02'nd Jun 2021
Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of symptoms compared to placebo in
Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients
07:02am, Wednesday, 02'nd Jun 2021
The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy
Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety
08:15am, Tuesday, 01'st Jun 2021
Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were
